Editorial
Treatment of Staphylococcus aureus in cystic fibrosis
| The first 150 words of the full text of this article appear below. |
A number of treatments for cystic fibrosis have evolved over the past four decades, based on the experience of clinicians involved in the care of these patients. Some of these treatments were developed without the benefit of large randomised controlled trials which would have been difficult to perform at the time. The value of prophylactic antibiotic treatment against Staphylococcus aureus in the management of infants and children is an example of a logical practice which has developed on the basis of experience, but which requires careful review as to its efficacy and potential deleterious effects.
Pulmonary infection with S aureus is a
frequent problem in patients with cystic fibrosis, particularly during
the first decade of life.1 Cross sectional studies show
that in this age group, 25
30% of patients culture
S aureus from sputum.2 This may be an underestimate as cough swabs in children unable to expectorate are often negative
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
